Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Revance Therapeutics (RVNC)
Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Revance Therapeutics 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 USA

www.revance.com P: 615-724-7755 F: 510-742-3401

Description:

Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS' peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.

Key Statistics

Overview:

Market Capitalization, $K 471,556
Enterprise Value, $K 362,586
Shares Outstanding, K 87,813
Annual Sales, $ 132,570 K
Annual Net Income, $ -356,420 K
Last Quarter Sales, $ 56,780 K
Last Quarter Net Income, $ -141,180 K
EBIT, $ -222,550 K
EBITDA, $ -183,700 K
60-Month Beta 0.99
% of Insider Shareholders 5.10%
% of Institutional Shareholders 93.28%
Float, K 83,335
% Float 94.90%
Short Volume Ratio 0.45

Growth:

1-Year Return -83.94%
3-Year Return -79.78%
5-Year Return -69.00%
5-Year Revenue Growth 50,888.46%
5-Year Earnings Growth -22.19%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.74 on 11/08/23
Latest Earnings Date 02/27/24
Earnings Per Share ttm -4.10
EPS Growth vs. Prev Qtr 7.50%
EPS Growth vs. Prev Year 36.75%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

RVNC Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -59.66%
Profit Margin % -268.85%
Debt/Equity -0.09
Price/Sales 2.06
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -1.21
Interest Coverage -20.60
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar